Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 08, 2021 at 08:01 PM UTC
Internal link ProQR Announces Virtual Presentation at EURETINA 2021
September 06, 2021 at 08:15 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences
September 03, 2021 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
August 11, 2021 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2021 Operating and Financial Results
August 05, 2021 at 11:00 AM UTC
Internal link ProQR to Present at Upcoming JMP Securities Life Sciences Conference
June 10, 2021 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2021 Operating and Financial Results
May 06, 2021 at 11:00 AM UTC
Internal link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
May 04, 2021 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
April 23, 2021 at 11:00 AM UTC
Internal link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
April 22, 2021 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 20, 2021 at 11:00 AM UTC
Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
April 13, 2021 at 08:15 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 05, 2021 at 08:15 PM UTC
Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
April 02, 2021 at 08:15 PM UTC
Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
March 31, 2021 at 02:25 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
March 30, 2021 at 08:05 PM UTC
Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 24, 2021 at 11:00 AM UTC
Internal link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
March 02, 2021 at 09:30 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
February 25, 2021 at 12:00 PM UTC
Internal link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
February 16, 2021 at 09:30 PM UTC
Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
January 07, 2021 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
December 17, 2018 at 04:52 PM UTC

Press releases

Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

Internal link ProQR Announces Virtual Presentation at EURETINA 2021

Internal link ProQR Announces Upcoming Investor Conferences

Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

Internal link ProQR Announces Second Quarter 2021 Operating and Financial Results

Internal link ProQR to Present at Upcoming JMP Securities Life Sciences Conference

Internal link ProQR Announces First Quarter 2021 Operating and Financial Results

Internal link ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Internal link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

Internal link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference

Internal link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results

Internal link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index

Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10

Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10